相关实验视频

Updated: Jan 15, 2026

Quantitative Autonomic Testing

Quantitative Autonomic Testing

Published on: July 19, 2011

纯自主性衰竭中的心脏MIBG光束学:系统性审查

Vittorio Velucci¹, Fabrizio De Pizzo¹, Giammarco Milella²

¹Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy.

Journal of the neurological sciences

|October 10, 2025

概括

在大多数纯自主性衰竭 (PAF) 患者中,心脏MIBG光谱异常. 保存的MIBG摄入量可能表明患帕金森病的风险更高.

科学领域:

神经学神经学
核医学是一种核医学.
自主神经科学自主神经科学

背景情况:

纯自主失败 (PAF) 是一种影响自主神经系统的α-synucleinopathy.
PAF可以是帕金森病 (PD) 的早期阶段,患有勒维体 (DLB) 的痴呆症或多个系统缩 (MSA).
心脏123I-metaiodobenzylguanidine (MIBG) 扫描在PAF中的作用需要进一步调查.

研究的目的:

评估PAF患者心脏MIBG扫描的诊断和预后价值.
确定MIBG光学扫描在预测PAF患者的变异现象的有用性.

主要方法:

系统审查病例报告和涉及PAF患者的病例系列,这些患者接受了心脏MIBG扫描.
数据提取包括人口,临床和光学发现,遵守PRISMA指南.
分析了39个案例 (38个来自文献,1个未发表).

主要成果:

在39名PAF患者中,在84.6%的患者中检测到异常的心脏MIBG光谱.
在3例异常MIBG吸收 (PD,DLB) 的病例中,发生了向中枢神经系统同核蛋白病变的转化.
五例正常的MIBG吸收进展到同核蛋白病变 (MSA,PD).

结论:

心脏MIBG扫描显示,大多数临床诊断的PAF患者的吸收异常.
在PAF患者中保存的MIBG吸收可能预测更高的转化概率,特别是MSA.
MIBG光学扫描为PAF及其进展提供了潜在的诊断和预后见解.

关键词:

123I-metaiodobenzylguanidine的使用情况心脏MIBG光阴学扫描.这是PAF的PAF.转换是一种转换.纯粹的自主性故障纯粹的自主性故障

更多相关视频

Location, Dissection, and Analysis of the Murine Stellate Ganglion

Location, Dissection, and Analysis of the Murine Stellate Ganglion

Published on: December 22, 2020

Assessment of Cardiac Function and Energetics in Isolated Mouse Hearts Using 31P NMR Spectroscopy

Assessment of Cardiac Function and Energetics in Isolated Mouse Hearts Using 31P NMR Spectroscopy

Published on: August 31, 2010

相关概念视频

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Imaging Studies for Cardiovascular System IV: CMRI

Imaging Studies for Cardiovascular System IV: CMRI

Cardiovascular magnetic resonance imaging, or CMRI, is a non-invasive diagnostic test that employs a magnetic field and radiofrequency waves to create precise images of the heart and arteries. It provides comprehensive information about cardiac anatomy, function, perfusion, and tissue characterization without ionizing radiation.IndicationsCMRI diagnoses various heart conditions, including tissue damage from heart attacks, ischemic heart disease, myocarditis, aortic issues (tears, aneurysms,...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Cardiomyopathy VI: Nursing Management

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...